The Lewy Body Dementia Association (LBDA) is the leading organization dedicated to raising awareness and providing support for people affected by Lewy body dementia (LBD). LBD is the second most common form of neurodegenerative dementia after Alzheimer's disease, affecting approximately 1.4 million Americans. The organization serves patients, families, caregivers, and healthcare professionals through education, support services, and research advocacy.
A network of specialized clinical centers providing expert diagnosis and care while advancing LBD research. These centers conduct clinical trials, collect biospecimens, and contribute to understanding LBD pathophysiology.
LBDA actively promotes and supports clinical trials specific to LBD, including trials targeting:
LBDA has contributed to numerous recent discoveries:
| Disease | Research Priority |
|---|---|
| Dementia with Lewy Bodies | Primary focus |
| Parkinson's Disease Dementia | Synuclein pathology |
| Pure Autonomic Failure | Alpha-synuclein |
| Multiple System Atrophy | Related synucleinopathies |
LBDA invests in educating healthcare professionals:
LBDA works with global partners:
LBDA plays a crucial role in advancing LBD research through:
The organization influences healthcare policy through:
The study of Lewy Body Dementia Association has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.